Kiromic BioPharma, Inc.
KRBP · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $0 | $0 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | -$5 | $4 | $4 | $3 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | -$1 | $0 |
| Other Operating Expenses | $8 | $0 | $0 | $0 |
| Operating Expenses | $6 | $7 | $6 | $5 |
| Operating Income | -$6 | -$7 | -$6 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$6 | -$7 | -$7 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$7 | -$7 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.31 | -4.59 | -4.71 |
| % Growth | 0% | 93.2% | 2.5% | – |
| EPS Diluted | -0.31 | -0.31 | -4.59 | -4.71 |
| Weighted Avg Shares Out | 29 | 31 | 45 | 39 |
| Weighted Avg Shares Out Dil | 29 | 31 | 45 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$5 | -$6 | -$5 | -$5 |
| % Margin | – | – | – | – |